Abstract

Hodgkin's lymphoma (HL) is a clonal lymphoid malignancy that affects over 7000 patients in the United States annually. The disease remains one of the great success stories in the recent history of cancer treatment. More than 80% of HL patients will be expected to be long-term survivors because of recent advances in radiation therapy and combined chemotherapy. However, for the subset of patients who relapse after initial therapy, HL remains a challenging disease. Indeed, for patients who relapse after salvage high-dose chemotherapy and autologous stem cell transplant, effective therapeutic options remain limited, and further new therapies are warranted. This article provides a review of the current literature regarding salvage therapy for HL.

Original languageEnglish (US)
Pages (from-to)161-163
Number of pages3
JournalCancer Journal
Volume15
Issue number2
DOIs
StatePublished - Mar 1 2009

Fingerprint

Salvage Therapy
Hodgkin Disease
Recurrence
Drug Therapy
Therapeutics
Survivors
Neoplasms
Radiotherapy
Stem Cells
History
Transplants

Keywords

  • Autologous stem cell transplant
  • Hodgkin's lymphoma
  • Salvage therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Salvage therapy for Hodgkin's lymphoma. / Quddus, Fahd; Armitage, James Olen.

In: Cancer Journal, Vol. 15, No. 2, 01.03.2009, p. 161-163.

Research output: Contribution to journalReview article

Quddus, Fahd ; Armitage, James Olen. / Salvage therapy for Hodgkin's lymphoma. In: Cancer Journal. 2009 ; Vol. 15, No. 2. pp. 161-163.
@article{b047cf2533f4410f9489cf165d309b75,
title = "Salvage therapy for Hodgkin's lymphoma",
abstract = "Hodgkin's lymphoma (HL) is a clonal lymphoid malignancy that affects over 7000 patients in the United States annually. The disease remains one of the great success stories in the recent history of cancer treatment. More than 80{\%} of HL patients will be expected to be long-term survivors because of recent advances in radiation therapy and combined chemotherapy. However, for the subset of patients who relapse after initial therapy, HL remains a challenging disease. Indeed, for patients who relapse after salvage high-dose chemotherapy and autologous stem cell transplant, effective therapeutic options remain limited, and further new therapies are warranted. This article provides a review of the current literature regarding salvage therapy for HL.",
keywords = "Autologous stem cell transplant, Hodgkin's lymphoma, Salvage therapy",
author = "Fahd Quddus and Armitage, {James Olen}",
year = "2009",
month = "3",
day = "1",
doi = "10.1097/PPO.0b013e3181a1438a",
language = "English (US)",
volume = "15",
pages = "161--163",
journal = "Cancer journal (Sudbury, Mass.)",
issn = "1528-9117",
publisher = "Association Pour le Developpement de la Communication Cancerologique",
number = "2",

}

TY - JOUR

T1 - Salvage therapy for Hodgkin's lymphoma

AU - Quddus, Fahd

AU - Armitage, James Olen

PY - 2009/3/1

Y1 - 2009/3/1

N2 - Hodgkin's lymphoma (HL) is a clonal lymphoid malignancy that affects over 7000 patients in the United States annually. The disease remains one of the great success stories in the recent history of cancer treatment. More than 80% of HL patients will be expected to be long-term survivors because of recent advances in radiation therapy and combined chemotherapy. However, for the subset of patients who relapse after initial therapy, HL remains a challenging disease. Indeed, for patients who relapse after salvage high-dose chemotherapy and autologous stem cell transplant, effective therapeutic options remain limited, and further new therapies are warranted. This article provides a review of the current literature regarding salvage therapy for HL.

AB - Hodgkin's lymphoma (HL) is a clonal lymphoid malignancy that affects over 7000 patients in the United States annually. The disease remains one of the great success stories in the recent history of cancer treatment. More than 80% of HL patients will be expected to be long-term survivors because of recent advances in radiation therapy and combined chemotherapy. However, for the subset of patients who relapse after initial therapy, HL remains a challenging disease. Indeed, for patients who relapse after salvage high-dose chemotherapy and autologous stem cell transplant, effective therapeutic options remain limited, and further new therapies are warranted. This article provides a review of the current literature regarding salvage therapy for HL.

KW - Autologous stem cell transplant

KW - Hodgkin's lymphoma

KW - Salvage therapy

UR - http://www.scopus.com/inward/record.url?scp=68049131240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68049131240&partnerID=8YFLogxK

U2 - 10.1097/PPO.0b013e3181a1438a

DO - 10.1097/PPO.0b013e3181a1438a

M3 - Review article

C2 - 19390313

AN - SCOPUS:68049131240

VL - 15

SP - 161

EP - 163

JO - Cancer journal (Sudbury, Mass.)

JF - Cancer journal (Sudbury, Mass.)

SN - 1528-9117

IS - 2

ER -